Stuart Ashman will succeed Professor Cath O’Neill as CEO after a period of transition.

Stuart Ashman is the new executive director of SkinBioTherapeutics.

Mr. Ashman will succeed Professor Cath O’Neill as CEO after a period of transition. Ms. O’Neill will continue to drive the science and the ongoing commercial discussions she has initiated.

He brings more than two decades of commercial healthcare experience, primarily in the medical devices industry, having held senior-level positions in a range of large public and smaller private companies.

Since 2014, Mr. Ashman has served as CEO of Onbone Oya, a Finnish private equity-backed medical device company.

Prior to that, he was President/CEO of Andover Healthcare Inc., a US-based wound management manufacturer and President/CEO of TI Group, a UK-based medical/engineering company. Mr. Ashman also served as Senior VP, Global Sales & Strategic Marketing,  BSN Medical (Biersdorf, Smith and Nephew) and was Director of Sales & Marketing at Smith & Nephew Plc, in its Woundcare, Casting & Bandaging division.